Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, has announced that it has entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences for up to US$1.3 billion in flexible, non-dilutive total capital to support the continued development and potential commercialization of zumilokibart.
Latham & Watkins LLP is advising Apogee in the strategic financing with a team led by partners Haim Zaltzman, Todd Trattner, and Dan Van Fleet, with associates Jing Cao and William Lane. Advice was also provided on tax matters by partner Eric Cho.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
